Followers | 664 |
Posts | 46911 |
Boards Moderated | 2 |
Alias Born | 03/30/2009 |
Thursday, July 31, 2014 1:34:07 PM
-- Starting in September, and continuing through the fall, there will be some significant developments and milestones met.
-- They will be expanding their R&D efforts and hiring people of the same caliber as Dr. Pierce.
-- Fundamentally, OncoSec is sound. The whole sector has been taking a hit ever since Janet Yellin mentioned something about biotech being in a bubble.
-- They are not writing off Neopulse but will focus all of their efforts on Immunopulse. If they did move forward with Neopulse at this time, it would negatively impact Immunopulse and Punit intends that OncoSec be THE leader in Immunopulse.
--OncoSec will continue to focus on converting non-responders into responders (IMO, this might be their "niche").
$ONCS
Saving up your money for a rainy day,
Giving all your clothes to charity.
Last night the wife said,
"Oh boy, when you're dead
You don't take nothing with you
But your soul - think!"
(Lennon/McCartney, "The Ballad of John and Yoko")
Recent ONCSQ News
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/13/2024 07:30:19 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM